Using a predefined formula and cutoff value, the division of CRC patients with and without recurrence was up to 85.7% sensitivity and 87.2% specificity, which superior to the traditional tumor marker, CEA and CA 19-9. This evidence concerns the gene CEACAM5 and neoplasm.